Roctavian: Biomarin’s First Gene Therapy For Hemophilia A Makes Headway
People with hemophilia A have a mutation in the gene responsible for producing factor VIII, a protein that stops bleeding by helping the blood form clots. BioMarin’s new gene therapy for hemophilia A, Roctavian, delivers a functional factor VIII gene to the body to help it produce the clotting factor by itself.
More Info : https://myacare.com/blog/roctavian-biomarins-first-gene-therapy-for-hemophilia-a-makes-headway
People with hemophilia A have a mutation in the gene responsible for producing factor VIII, a protein that stops bleeding by helping the blood form clots. BioMarin’s new gene therapy for hemophilia A, Roctavian, delivers a functional factor VIII gene to the body to help it produce the clotting factor by itself.
More Info : https://myacare.com/blog/roctavian-biomarins-first-gene-therapy-for-hemophilia-a-makes-headway
Roctavian: Biomarin’s First Gene Therapy For Hemophilia A Makes Headway
People with hemophilia A have a mutation in the gene responsible for producing factor VIII, a protein that stops bleeding by helping the blood form clots. BioMarin’s new gene therapy for hemophilia A, Roctavian, delivers a functional factor VIII gene to the body to help it produce the clotting factor by itself.
More Info : https://myacare.com/blog/roctavian-biomarins-first-gene-therapy-for-hemophilia-a-makes-headway
0 Comments
0 Shares
678 Views
0 Reviews
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek